v3.25.4
SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Details Narrative) - USD ($)
3 Months Ended 9 Months Ended 12 Months Ended
Sep. 30, 2025
Sep. 30, 2025
Dec. 31, 2024
Dec. 31, 2023
Common stock par value $ 0.0001 $ 0.0001 $ 0.0001  
Additional paid in capital $ 11,078,116 $ 11,078,116 $ 1,234,385  
Federal deposit Insurance corporation coverage limit 250,000 250,000    
Excess of FDIC insurance limit 1,678,669 1,678,669 0  
Cash equivalents 0 0 0  
Unrecognized tax benefits 0 0 $ 0  
Income tax penalties and interest expense $ 0 $ 0    
Aspire Biopharma Inc [Member]        
Common stock par value     $ 0.00005 $ 0.00005
Post split par value       $ 0.00005
Additional paid in capital     $ 1,215,113 $ 957,500
Shares issued       150,000
Aspire Biopharma Inc [Member] | Trademarks [Member]        
Amortization of long lived assets     $ 4,844,982  
Previously Reported [Member] | Aspire Biopharma Inc [Member]        
Common stock par value     $ 0.01  
Additional paid in capital       $ 758,000
Revision of Prior Period, Adjustment [Member] | Aspire Biopharma Inc [Member]        
Common stock par value       $ 0.001
Additional paid in capital       $ 957,500
Effect of Restatement [Member] | Aspire Biopharma Inc [Member]        
Additional paid in capital       $ 199,500